iECURE raises funds to advance gene-editing programmes
Co-led by LYFE Capital and Novo Holdings, the financing round has also seen participation from existing investors OrbiMed Advisors and Versant Ventures. The latest funding will bring iECURE’s
The second-generation PDT photosensitiser drug, REM-001 has undergone late-stage clinical development in previous clinical trials. The REM-001 therapy includes three parts, a laser light source, a light delivery
The application has been submitted for the combination of toripalimab, cisplatin and gemcitabine as the first-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma (NPC) patients. The company